TIPS Versus Portacaval Shunt for Acute Bleeding Varices in Cirrhosis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In unselected cirrhotic patients with acute portal hypertension-related bleeding to compare the effectiveness in control of bleeding, mortality rate, duration of life, quality of life, and economic costs of two widely used treatment measures: (1) emergency transjugular intrahepatic portal-systemic shunt (TIPS), and (2) emergency portacaval shunt.
| Condition | Intervention |
|---|---|
|
Bleeding |
Procedure: Emergency portacaval shunt Other: Emergency TIPS |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single Blind (Investigator) Primary Purpose: Treatment |
| Official Title: | TIPS Versus Portacaval Shunt for Acute Bleeding Varices in Cirrhosis |
- Survival [ Time Frame: 10 years ]
- Control of bleeding and quality of life [ Time Frame: 10 years ]
| Enrollment: | 153 |
| Study Start Date: | July 1996 |
| Study Completion Date: | July 2006 |
| Primary Completion Date: | October 2003 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: A
Randomization: By the blind card method to TIPS or emergency portacaval shunt. Diagnostic Workup: Completed within 6hr. Rapidity of Therapy: Within 24 hr. Failure of Therapy: Bleeding requiring >6u PRBC in first 7 days, or 8 units PRBC during 12 months. Rescue Crossover Therapy: When primary therapy has failed. Followup: Lifelong data collection on line, analysis by biostatistician Florin Vaida, PhD. External Advisory, Data Monitoring and Safety Committee by 3 senior academicians. Procedure: Emergency portacaval shunt. |
Procedure: Emergency portacaval shunt |
|
Active Comparator: B
Procedure: Emergency TIPS.
|
Other: Emergency TIPS |
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- All patients with UGI bleeding who are shown to have the findings of cirrhosis and esophagogastric varices or portal hypertensive gastropathy and require 2 or more units of blood transfusion will be included.
Exclusion Criteria:
- None
Contacts and Locations| United States, California | |
| UCSD Medical Center | |
| San Diego, California, United States, 92103 | |
| Principal Investigator: | Marshall J. Orloff, M.D. | UCSD Medical Center |
More Information
No publications provided by University of California, San Diego
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Marshall J. Orloff, M.D., University of California, San Diego |
| ClinicalTrials.gov Identifier: | NCT00734227 History of Changes |
| Other Study ID Numbers: | TvSSTUDY |
| Study First Received: | August 13, 2008 |
| Last Updated: | August 13, 2008 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of California, San Diego:
|
Survival and control of hemorrhage |
Additional relevant MeSH terms:
|
Hemorrhage Fibrosis Varicose Veins |
Pathologic Processes Vascular Diseases Cardiovascular Diseases |
ClinicalTrials.gov processed this record on May 16, 2013